Ionis Pharmaceuticals, Inc. (IONS) News

Ionis Pharmaceuticals, Inc. (IONS): $45.20

-0.99 (-2.14%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Filter IONS News Items

IONS News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

IONS News Highlights

  • For IONS, its 30 day story count is now at 12.
  • Over the past 22 days, the trend for IONS's stories per day has been choppy and unclear. It has oscillated between 1 and 4.
  • The most mentioned tickers in articles about IONS are III, MET and PRAX.

Latest IONS News From Around the Web

Below are the latest news stories about IONIS PHARMACEUTICALS INC that investors may wish to consider to help them evaluate IONS as an investment opportunity.

3 Biotech Stocks to Sell in October

These biotech stocks to sell are at a cross roads with their businesses with few growth catalysts ahead amid this turbulent market.

Muslim Farooque on InvestorPlace | September 29, 2022

Arthur Tzianabos, Ph.D., June Lee, MD FACCP, and Joseph Loscalzo, MD, Ph.D. Join 5AM Ventures

Enhancing the depth of 5AM’s scientific and operational expertiseSAN FRANCISCO and BOSTON, Sept. 27, 2022 (GLOBE NEWSWIRE) -- 5AM Ventures, a bicoastal venture capital firm, continues to attract preeminent talent as it celebrates 20 years of investing in early-stage life science companies. The firm is currently deploying capital in breakthrough science opportunities throughout North America and Europe from its $450 million 5AM Ventures VII fund and its $300 million 5AM Opportunities II fund, whi

Yahoo | September 27, 2022

Ionis Pharmaceuticals Nosedives After AstraZeneca Drops High Cholesterol Drug Test

Ionis stock tumbled Friday after partner AstraZeneca decided against sending their high cholesterol treatment into Phase 3 testing.

Yahoo | September 23, 2022

Ionis' (IONS) Hypercholesterolemia Drug Not to Enter Phase III

Ionis (IONS) posts data from the phase IIb SOLANO study on ION449 for treating hypercholesterolemia. Though the study met the primary endpoint, ION449 will not advance into phase III development.

Yahoo | September 23, 2022

AstraZeneca Pulls Plug On Ionis Pharma-Partnered Cholesterol Med

Ionis Pharmaceuticals Inc (NASDAQ: IONS) announced topline data from the Phase 2b SOLANO study of ION449 (AZD8233) for hypercholesterolemia (high cholesterol levels). Ionis said that although the candidate met the primary endpoint, its partners at AstraZeneca Plc (NASDAQ: AZN) have decided not to move it into Phase III studies because the "results did not achieve pre-specified efficacy criteria." The trial showed that 60mg of ION449 (AZD8233) administered monthly achieved a statistically signifi

Yahoo | September 23, 2022

Ionis provides update on development program evaluating PCSK9 antisense medicine for the treatment of hypercholesterolemia

Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that topline results from the Phase 2b SOLANO study in patients with hypercholesterolemia demonstrated that 60mg of ION449 (AZD8233) administered monthly achieved a statistically significant 62.3% (p<0.001) reduction in low-density lipoprotein cholesterol (LDL-C) levels after 28 weeks compared to placebo, meeting the study's primary efficacy endpoint. ION449 was generally safe and well tolerated in this study. However, these results did

Yahoo | September 23, 2022

The 7 Best Biotech Stocks to Buy

The best biotech stocks to buy are a lot like the best computer stocks 40 years ago; the biggest similarity is how hard they are to predict.

Dana Blankenhorn on InvestorPlace | September 20, 2022

Invitae’s Real-World Ciitizen Data Utilized in Praxis Precision Medicines’ PRAX-222 IND Filing

First use of Ciitizen platform as source of real-world data in regulatory filingSAN FRANCISCO and BOSTON, Sept. 20, 2022 (GLOBE NEWSWIRE) -- Invitae (NYSE: NVTA) and Praxis Precision Medicines, Inc. (NASDAQ: PRAX), today announced that real-world clinical insights from Invitae’s Ciitizen platform were utilized as natural history data to support the submission of Praxis’ Investigational New Drug (IND) application for PRAX-222 for the treatment of pediatric patients with early-onset SCN2A developm

Yahoo | September 20, 2022

Strength Seen in Esperion Therapeutics (ESPR): Can Its 5.7% Jump Turn into More Strength?

Esperion Therapeutics (ESPR) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Yahoo | September 16, 2022

There's 'Outsized' Risk-Reward For This Biotech, Morgan Stanley Says, Predicting Shares Could Grow More Than 30%

Morgan Stanley has assumed coverage on Ionis Pharmaceuticals Inc (NASDAQ: IONS) with an Overweight (previously Underweight) rating and a price target of $57 from $30 to capture the optionality in these near-term readouts. The analyst has added estimates for Ionis's near-term pipeline products (donidalorsen, fesomersen, IONIS-AGT-LRx, IONIS-FBLRx, and cimdelirsen) as well as associated increases in operating expenses to fund these programs. Related: AstraZeneca - Ionis Eplontersen Achieves Positi

Yahoo | September 9, 2022


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.5747 seconds.